Medetocord 1 mg/ml Solution for Injection for Dogs and Cats

It is possible that medetomidine does not provide analgesia throughout the entire
sedation period. The use of additional analgesics should be considered during painful
surgical procedures.

Special precautions for safe use in the target species:
During its use in premedication, the dosage of anaesthetic will be reduced in
proportion and established according to the reaction of the animal, depending on the
variability of response between animals. Special warnings and contraindications
included in the literature of the other products should be respected before carrying
out any association.
Medetomidine can produce respiratory depression; in such case, manual ventilation
and administration of oxygen may be conducted.
A clinical examination should be carried out in all animals before the use of veterinary
medicinal products for sedation and/or general anaesthesia.
Higher doses of medetomidine should be avoided in large breed dogs. Care should
be taken when combining medetomidine with other anaesthetics or sedatives
because of its marked anaesthetic sparing effects. Animals should be fasted 12
hours before anaesthesia.
The animal should be placed in a calm and quiet surrounding to let the sedation gain
its maximum effect. This takes about 10-15 minutes. One should not start any
procedure or give other medicines before maximum sedation is reached.
Treated animals should be kept warm and at a constant temperature, both during the
procedure and recovery.
The eyes should be protected by a suitable lubricant.
Nervous, aggressive or excited animals should be given the possibility to calm down
before initiation of treatment
AN: 00451/2024 & 00452/2024
Sick and debilitated dogs and cats should only be premedicated with medetomidine
before induction and maintenance of general anaesthesia based on a risk-benefit
assessment.
Care should be taken with use of medetomidine in animals with cardiovascular
disease, or which are elderly or in general poor health. Liver and kidney function
should be evaluated prior to use.
In order to reduce the recovery time after anæsthesia or sedation, the effect of
medetomidine can be reversed by the administration of an alpha-2-antagonist such
as atipemazole.
Atipamezole does not reverse the effect of ketamine. As ketamine alone can elicit
cramps, alpha-2 antagonists should not be given less than 30-40 min. after the
administration of ketamine.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental oral intake or self-injection, seek medical advice immediately
and show the package leaflet or the label to the physician but DO NOT DRIVE as
sedation and changes in blood pressure may occur.
Avoid skin, eye or mucosal contact.
Wash the exposed skin immediately after exposure with large amounts of water.
Remove contaminated clothes that are in direct contact with skin.
In the case of accidental contact of the product with eyes, rinse abundantly with fresh
water. If symptoms occur, seek the advice of a physician.
If pregnant women handle the product, special caution should be observed not to
self-inject as uterine contractions and decreased foetal blood pressure may occur
after accidental systemic exposure.
Advice to doctors:
Medetomidine is an alpha2-adrenoreceptor agonist, symptoms after absorption may
involve clinical effects including dose-dependent sedation, respiratory depression,
bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias
have also been reported.
Respiratory and haemodynamic symptoms should be treated symptomatically.
AN: 00451/2024 & 00452/2024